Rafael Holdings, Inc.RFL
Price (close)
$1.91
Market cap
$97.8M
P/E
—
Revenue (TTM)
$980,000
Net income
-$20.7M
Dividend yield
—
1-year total return
40.4%
Net margin
-2117.2%
Revenue growth
33.9%
Debt / equity
—
What Rafael Holdings, Inc. does.
interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol®
Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”),
a rare, fatal and progressive genetic disorder. We also hold: (i) a majority equity interest in LipoMedix Pharmaceuticals Ltd. (“LipoMedix”),
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | $802,000 | $410,000 | $279,000 | $637,000 | $917,000 |
| Net income | -$10.8M | -$23.1M | -$124.7M | -$1.9M | -$34.4M | -$30.5M |
| Free cash flow | -$5.2M | -$15.8M | -$26.1M | — | -$7.9M | -$18.9M |
More on RFL.
- Rafael Holdings, Inc. summary
- Rafael Holdings, Inc. financial statements
- Rafael Holdings, Inc. key metrics
- Rafael Holdings, Inc. health scores and style box
- Rafael Holdings, Inc. earnings
- Rafael Holdings, Inc. dividends
- Rafael Holdings, Inc. valuation
- Rafael Holdings, Inc. ownership and insiders
- Rafael Holdings, Inc. peers
Figures from Rafael Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.